Overall survival with adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with high-risk HR+/HER2– early breast cancer: Six-year follow-up of the NATALEE trial
Overall survival with adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with high-risk HR+/HER2– early breast cancer: Six-year follow-up of the NATALEE trial. // Annals of Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S0923753426086400?dgcid=rss_sd_all
Overall survival with adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with high-risk HR+/HER2– early breast cancer: Six-year follow-up of the NATALEE trial. Annals of Oncology. https://www.sciencedirect.com/science/article/pii/S0923753426086400?dgcid=rss_sd_all
“Overall survival with adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with high-risk HR+/HER2– early breast cancer: Six-year follow-up of the NATALEE trial.” Annals of Oncology.
@article{article36283,
title = {Overall survival with adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with high-risk HR+/HER2– early breast cancer: Six-year follow-up of the NATALEE trial},
journal = {Annals of Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S0923753426086400?dgcid=rss_sd_all}
}